Eight weeks be­tween each HIV treat­ment? GSK notch­es PhI­II win as it chas­es OK for long-act­ing reg­i­men

GSK has cleared an­oth­er test in its grand plan to top­ple Gilead’s HIV dom­i­nance by of­fer­ing al­ter­na­tive treat­ments that con­sist of few­er drugs and last longer. A year af­ter scor­ing pos­i­tive Phase III da­ta on a four-week course of cabote­gravir and rilpivirine, its Vi­iV sub­sidiary now says that an eight-week reg­i­men seem to work just as well.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER